Reply to "Letter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis'".

Francesco DeodatoDonato PezzullaSavino CillaMilena FerroMilly BuwengeAlessio Giuseppe MorgantiGabriella Macchia

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)

Keyphrases

clinical trial
prostate cancer
benign prostatic hyperplasia
phase ii
open label
double blind
study protocol
phase iii